Anthropic Jumps 17% as AI Stock Rally Loses Ground
Anthropic rose 17% in its market debut, but the broader AI trade failed to follow. Major US indexes fell into correction territory as investors looked beyond technology to healthcare, financials and other sectors, while strategists pointed to a widening gap in stock performance.

Anthropic's market debut failed to revive the broader artificial intelligence trade, even as its shares surged 17%. The Dow Jones Industrial Average fell more than 1,000 points, while the S&P 500 and Nasdaq Composite each slid around 2%.
The sell-off continued. The S&P 500 and Dow entered correction territory, while the Nasdaq gave up its 2026 gains.
Strategists are looking beyond the AI stocks that led the bull market. They see potential opportunities in healthcare, financials, industrials and consumer companies.
Melissa Otto, global head of Visible Alpha Research at S&P Global, said investors need to understand company fundamentals and what is already reflected in share prices. “We have moved pretty dramatically into a stock pickers market,” she said.
Healthcare gains as technology falls
The iShares U.S. Technology ETF fell 13% over six months, while the iShares U.S. Healthcare ETF gained 21%. The iShares U.S. Financials ETF rose 4% over the same period.
Goldman Sachs said AI infrastructure stocks contributed nearly half the S&P 500's return since the AI-driven bull market began in late 2022. Nvidia alone accounted for 10%, the bank said.
JPMorgan said third-quarter earnings growth for the Magnificent Seven fell below that of the rest of the S&P 500. It was the first time that had happened since 2022.
The S&P 500 Equal Weight index, which gives each company the same weighting, gained 10% in 2026. It outperformed the version weighted by company market value.
The iShares Russell 1000 Value ETF advanced 19% year to date, while the growth-focused IWF fell 10%.
Strategists identify stocks beyond AI
David Keller, chief market strategist at Sierra Alpha Research, highlighted Johnson & Johnson and companies supplying medical devices. Johnson & Johnson shares gained 36% year to date.
Barbara Doran, founder and chief investment officer of BD8 Capital Partners, pointed to Eli Lilly, citing applications for its weight-loss drug. She also favored financial firms JPMorgan Chase, Goldman Sachs and Morgan Stanley.
Keller named exchanges Cboe Global Markets, CME Group and Intercontinental Exchange as financial stocks that had performed well despite volatility.
Doran also identified GE Vernova as a potential beneficiary of grid modernization and demand for electrical equipment. Its shares gained 7% year to date.
Otto is watching consumer stocks that could recover toward their historical valuations. Lululemon and Nike fell 50% and 47%, respectively, year to date.
FactSet said about 84% of S&P 500 companies that reported third-quarter earnings exceeded analyst expectations, above the five-year average of 78%. Goldman Sachs forecasts the index will reach 8,700 over the next 12 months.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Markets · FintechHow to Calculate Compound Interest: Formula, Examples and the Rule of 72
Lifestyle · Food & HealthNormal Blood Pressure Chart by Age: Healthy Ranges Explained
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say



















